Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Agios Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's EBIT?
- Agios Pharmaceuticals (AGIO) reported EBIT of -$110.55M in Q2 2026.
- How has Agios Pharmaceuticals's EBIT changed year-over-year?
- Agios Pharmaceuticals's EBIT increased by 13.0% year-over-year, from -$127.06M to -$110.55M.
- What is the long-term trend for Agios Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's EBIT has grown at a 5.7% compound annual growth rate (CAGR), from -$378.42M to -$472.13M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Agios Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude